Stanley Capital-backed LXO acquires Nimotop® from Bayer

Stanley Capital Partners (“Stanley Capital” / “SCP”), the specialist healthcare and resource efficiency private equity investor is pleased to announce that its portfolio company, Laboratoire X.O (“LXO”), has completed the acquisition of the prescription drug Nimodipine under the brand name Nimotop® from Bayer for several markets globally excluding mainland China.

Nimodipine is the only approved 2nd generation dihydropyridine calcium channel blocker that is available in three different formulations (oral tablets, oral solutions and intravenous infusion solutions) in several markets globally. It is used for the prevention and treatment of cerebral vasospasm, following an aneurysmal subarachnoid hemorrhage (“aSAH”), a type of stroke with high mortality and morbidity rates.  

The global cerebral vasospasm market is expected to grow at a CAGR of +6.5% (*2022A – 2027E), mainly driven by aging populations (at higher risk of experiencing aSAH and vasospasm), higher incidence of aSAH (with an increasing number of reported aSAH cases worldwide, the potential patient pool for vasospasm treatment is subsequently expanding) and general lifestyle behaviours.

This acquisition builds on Stanley Capital’s investment strategy of consolidating and integrating established medicines with high barriers to entry from big pharma companies. The overall aim is to create a high therapeutic value platform within a space where the firm has actively been investing since 2020. 

Patrick Hargutt, Founding Partner at Stanley Capital Partners, commented:
“Stanley Capital is actively working with LXO management team to further strengthen and support the company through its next phase of growth and wider development. The acquisition of Nimotop® follows a highly impressive M&A track record with now 20 add-on acquisitions completed to date and a clear strategy to pursue further bolt-ons from our actively curated pipeline in established medicines. Management have identified a clear path to implement its systemised late lifecycle management playbook for Nimotop® which includes enlarging its serviceable available market (“SAM”) through digital marketing, pursuing geographic expansion and also optimising market access.”

Please click for the full press release in PDF and word document.